The US FDA will put more teeth into its homeopathic drug industry oversight under a draft guidance that identifies problems it will target for enforcement while allowing the products to remain available without pre-market approval.
The draft guidance published Dec. 18 also does not specify testing of homeopathic ingredients for certain indications but states...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?